Estrogen enhancers tied to aggressive breast cancer
This work was supported by R01 CA069065, R01 ES017594, U01 ES015986 (Gene and Environment Initiative), U54 CA113001 (Integrative Cancer Biology Program), and P30 CA054174 (Cancer Center Support Grant) at the U.S. National Institutes of Health and by generous gifts from the Cancer Therapy & Research Center Foundation and the Max and Minnie Tomerlin Voelcker Fund.
Amplification of Distant Estrogen Response Elements Deregulates Target Genes Associated with Tamoxifen Resistance in Breast Cancer
Pei-Yin Hsu,1 Hang-Kai Hsu,1 Xun Lan,6 Liran Juan,9 Pearlly S. Yan,7 Jadwiga Labanowska,8 Nyla Heerema,8 Tzu-Hung Hsiao,4 Yu-Chiao Chiu,5 Yidong Chen,3,4 Yunlong Liu,9 Lang Li,9 Rong Li,1 Ian M. Thompson,2 Kenneth P. Nephew,10 Zelton D. Sharp,1 Nameer B. Kirma,1 Victor X. Jin,6 and Tim H.-M. Huang1,* Departments of 1 Molecular Medicine/Institute of Biotechnology, 2 Urology, and 3 Epidemiology and Biostatistics, 4 Greehey Children's Cancer Research Institute, Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, TX 78245, USA 5 Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan Departments of 6 Biomedical Informatics, 7 Molecular Virology, Immunology, and Medical Genetics, and 8 Pathology, The Ohio State University, Columbus, OH 43210, USA 9 Center of Computational Biology and Bioinformatics and Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA 10 Medical Sciences, Indiana University School of Medicine, Bloomington, IN 47405, USA
For current news from the UT Health Science Center San Antonio, please visit our news release website, like us on Facebook or follow us on Twitter.
About the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio
The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the elite academic cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of only four in Texas. A leader in developing new drugs to treat cancer, the CTRC Institute for Drug Development (IDD) conducts one of the largest oncology Phase I clinical drug programs in the world, and participates in development of cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit http:www.ctrc.net.
HOME [HSC NEWS]
| About UTHSCSA
| News Releases | Mission
Magazine | Grand Rounds Newly
Granted | Submit News | HSC
News Archive | Video Index